CAR-T Congress USA 2019

4th Annual CAR-T Congress USA is organized by Kisaco Research and will be held from Apr 16 - 17, 2019 at Hyatt Regency Boston Harbor, Boston, Massachusetts, United States of America.

Who will be there:
Network with industry experts from
• Big pharma and biotech
• Cell Therapy Academics and clinicians 
• Process standardisation - technology/services
• Logistics companies - cell storage/transport
• Service providers - CRO’s, Consultants, Government

Why Attend:
The fourth annual CAR-T congress USA is bringing together the leading pharmaceutical companies, the disruptive biotechs and pioneering academic institutions to assess emerging novel data and tackle the current challenges including antigen discovery, manufacturing scalability and efficacy.

Discover first-hand the novel research being done by one of the leading biotechs to watch, Tmunity, as we explore the potential of CAR-T switches to control and manage CAR-T therapy effectively. Join Fate Therapeutics, TCR2 and Cellectis to determine how novel CAR-T constructs and gene editing technology are paving the way for the next generation CAR-Ts.

You Will Learn:
• To optimize genome editing techniques from Precision Biosciences, ensuring on target precision and more efficacious CAR-T.
• Ways in which the EMA and FDA are supporting the development and approval of CAR-T therapies, ensuring global regulation.
• The framework MD Anderson Cancer Centre and Stanford Medical Centre are creating, to monitor, grade and manage common toxicities and improve product safety. 
• To interpret novel smallscale trial data on single patient experiences of CAR-T for Glioblastomas, Chronic
Lymphocytic Leukemia and Acute Myeloid Leukaemia, to inform a future clinical trial strategy.
• How 3T Biosciences are identifying novel antigen targets to prevent suppressive mechanisms in the tumor microenvironment and improve the efficacy of CAR-T. 
• To engineer antibodybased switches into CAR-T, enabling the development of inducible and controllable therapies that limit off target activity.
• To modify the tumour microenvironment, boost host immunity and develop immunological memory and improve efficacy in solid tumours by engineering natural killer cell receptors into CAR-T’s
• How pharmaceutical companies are improving patient support programmes to provide new market access models that will aid the commercialization of CAR-T
• Manufacturing methods using proprietary genome editing techniques and renewable iPSC lines to produce allogeneic CAR-T therapies at scale.
• How to ‘reawaken’ T cell phenotypes and optimize longevity of CAR-T, comparingthe efficacy of allogeneic and autologous therapiesin the pursuit of single dose treatments.

Additional details will be posted as soon as they are available.